


# Tata India Pharma & Healthcare Fund

(An open ended equity scheme investing in Pharma and Healthcare Services Sector)



As on 31st July 2022

## INVESTMENT STYLE

Primarily focuses on investment in at least 80% of its net assets in equity/equity related instruments of the companies in the Pharma & Healthcare sectors in India.

## INVESTMENT OBJECTIVE

The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The Scheme does not assure or guarantee any returns.

## DATE OF ALLOTMENT

December 28, 2015

## FUND MANAGER

Meeta Shetty (Managing Since 09-Mar-21 and overall experience of 15 years)

## BENCHMARK

Nifty Pharma TRI

## NAV

Direct - IDCW	:	18.1648
Direct - Growth	:	18.1648
Regular - IDCW	:	16.3231
Regular - Growth	:	16.3231

## FUND SIZE

Rs. 528.65 (Rs. in Cr.)

## MONTHLY AVERAGE AUM

Rs. 516.91 (Rs. in Cr.)

## TURN OVER

Portfolio Turnover (Equity component only) 30.29%

## EXPENSE RATIO\*\*

Direct	0.99
Regular	2.50

\*\*Note: The rates specified are actual month end expenses charged as on Jul 31, 2022. The above ratio includes the Service tax on Investment Management Fees. The above ratio excludes, borrowing cost, wherever applicable.

## VOLATILITY MEASURES ^ FUND BENCHMARK

Std. Dev (Annualised)	19.10	24.03
Sharpe Ratio	0.26	0.17
Portfolio Beta	0.74	1.00
R Squared	0.86	1.00
Treynor	1.95	1.15
Jenson	0.59	NA

^ Risk-free rate based on the FBIL Overnight MIBOR rate of 5.25% as on Jul 29, 2022

For calculation methodology please refer to Pg 74

## MINIMUM INVESTMENT / MULTIPLES FOR NEW INVESTMENT

Rs. 5,000/- and in multiples of Re. 1/- thereafter.

## ADDITIONAL INVESTMENT / MULTIPLES FOR EXISTING INVESTORS

Rs. 1,000/- and in multiples of Re. 1/- thereafter.

## LOAD STRUCTURE

Entry Load : Not Applicable

Exit Load : 0.25% of NAV if redeemed/switched out before 30 days from the date of allotment.

Please refer to our Tata Mutual Fund website for fundamental changes, wherever applicable



## PORTFOLIO

Company name	No. of Shares	Market Value Rs. Lakhs	% of Assets
<b>Equity &amp; Equity Related Total</b>		<b>52119.09</b>	<b>98.62</b>
<b>Healthcare Services</b>			
Apollo Hospitals Enterprise Ltd.	84300	3550.97	6.72
Fortis Healthcare Ltd.	1005100	2798.70	5.29
Krishna Institute Of Medical Sciences Ltd.	116982	1452.86	2.75
Healthcare Global Enterprises Ltd.	476121	1283.15	2.43
Narayana Hrudayalaya Ltd.	128176	844.62	1.60
<b>Insurance</b>			
ICICI Lombard General Insurance Co. Ltd.	45000	548.96	1.04
<b>Pharmaceuticals &amp; Biotechnology</b>			
Sun Pharmaceutical Industries Ltd.	912100	8602.93	16.27
Dr Reddys Laboratories Ltd.	148200	6061.90	11.47
Cipla Ltd.	605000	5913.27	11.19
Alkem Laboratories Ltd.	103049	3323.48	6.29
Ipca Laboratories Ltd.	317452	3175.31	6.01
Lupin Ltd.	323000	2080.44	3.94
J.B.Chemicals & Pharmaceuticals Ltd.	103000	1823.20	3.45
Aurobindo Pharma Ltd.	255000	1394.85	2.64
Divi Laboratories Ltd.	35000	1341.08	2.54
Fdc Ltd.	471283	1194.70	2.26
Procter & Gamble Health Ltd.	26000	1152.55	2.18
Indoco Remedies Ltd.	276851	1066.71	2.02
Abbott India Ltd.	5100	1020.77	1.93
Gland Pharma Ltd.	35662	806.16	1.52
Ajanta Pharma Ltd.	58129	743.24	1.41
Glenmark Pharmaceuticals Ltd.	167000	636.02	1.20

## SIP - If you had invested INR 10000 every month

	1 Year	3 Year	5 Year	7 Year	10 Year	Since Inception
Total Amount Invested (Rs.)	1,20,000	3,60,000	6,00,000	NA	NA	7,90,000
Total Value as on Jul 31, 2022 (Rs.)	1,14,962	4,56,344	9,03,943	NA	NA	12,37,093
Returns	-7.79%	16.11%	16.45%	NA	NA	13.46%
Total Value of B: Nifty Pharma TRI	1,13,678	4,30,225	7,75,905	NA	NA	10,08,397
B: Nifty Pharma TRI	-9.75%	11.98%	10.25%	NA	NA	7.33%
Total Value of AB: Nifty 50 TRI	1,22,098	4,78,696	8,80,184	NA	NA	12,96,724
AB: Nifty 50 TRI	3.30%	19.51%	15.36%	NA	NA	14.87%

(Inception date :28-Dec-2015) (First Installment date : 01-Jan-2016)

Past performance may or may not be sustained in the future. Returns greater than 1 year period are compounded annualized. Income Distribution cum capital withdrawals are assumed to be reinvested and bonus is adjusted. Load is not taken in to consideration. For SIP returns, monthly investment of equal amounts invested on the 1st day of every month has been considered.

For scheme performance refer pages 58 - 72.

\*B: Benchmark, AB: Additional Benchmark; For Scheme Risk-O-Meter and Scheme Benchmark Risk-O-Meter please refer page number 73 of Factsheet.

Source: MFI Explorer

## Top 10 Holdings Equity

Issuer Name	% to NAV
Sun Pharmaceutical Industries Ltd.	16.27
Dr. Reddys Laboratories Ltd.	11.47
Cipla Ltd.	11.19
Apollo Hospitals Enterprise Ltd.	6.72
Alkem Laboratories Ltd.	6.29
Ipca Labs	6.01
Fortis Healthcare Ltd.	5.29
Lupin Laboratories Ltd.	3.94
J.b.chemicals & Pharmaceuticals Ltd.	3.45
Krishna Institute Of Medical Sciences Ltd.	2.75
<b>Total</b>	<b>73.38</b>

## Market Capitalisation wise Exposure


Large Cap	51.47%
Mid Cap	27.85%
Small Cap	20.68%

Market Capitalisation is as per list provided by AMFI.

Company name	No. of Shares	Market Value Rs. Lakhs	% of Assets
<b>Other Equities ^</b>		<b>1303.22</b>	<b>2.47</b>
<b>Repo</b>		<b>806.05</b>	<b>1.52</b>
<b>Portfolio Total</b>		<b>52925.14</b>	<b>100.11</b>
<b>Net Current Liabilities</b>		<b>-60.43</b>	<b>-0.11</b>
<b>Net Assets</b>		<b>52864.71</b>	<b>100.00</b>

^ Exposure less than 1% has been clubbed under Other Equities

## Sector Allocation



## NAV Movement

